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Abstract
Background: It is still a matter of debate whether there is an association between infection with
Mycobacterium tuberculosis (M. tuberculosis) and allergy. Previously, we have shown higher levels of
specific IgE to different inhalant allergens and total IgE in tuberculosis (TB) patients compared to
controls. The objectives of this study were to evaluate a possible change in allergic sensitisation
after successful TB treatment and to confirm the finding of our previous study of enhanced allergic
sensitisation in TB patients compared to controls in a more controlled setting. Additionally, we
wanted to determine the cytokine profile in the same groups and finally to evaluate the association
between the presence of Bacillus Calmette-Guérin vaccination (BCG) scar and allergic sensitisation
among the controls.
Methods: Sera were analysed for specific IgE to inhalant allergens (Phadiatop) and total IgE by the
use of ImmunoCAP 1000 (Pharmacia Diagnostics). Thirteen different cytokines were also analysed
in the sera by multiplex bead immunoassay (Luminex 100, Luminex Corporation), and clinical
symptoms of allergy and BCG scar were reported in a questionnaire.
Results: A reduction in levels of specific and total IgE were observed after successful TB treatment.
TB patients also had higher levels of specific and total IgE compared to healthy controls. Both
interleukin (IL)-6 and interferon (IFN)γ were higher in TB patients compared to healthy controls.
The levels of IL-6 were reduced after successful TB treatment. The presence of a BCG scar was
associated with a reduced risk of developing allergic sensitisation.
Conclusion: We observed a reduced level of allergic sensitisation after successful TB treatment.
TB patients seem to be more allergically sensitised than healthy controls, confirming our previous
finding. Furthermore, we observed an inverse association between allergic sensitisation and visible
BCG scar, which adds additional support to the hygiene hypothesis.
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Background
Infections with M. tuberculosis remain a major health
problem around the world, leading to 2–3 million deaths
annually. There are 7–8 million new cases of TB every year
[1], and a third of the human population has been esti-
mated to be infected by M. tuberculosis. While TB is a prob-
lem in developing countries, allergy has been an
increasing problem in developed countries. In 1989 Stra-
chan proposed the hygiene hypothesis, stating that an
increase in allergy could be a result of reduced childhood
infections [2]. The mechanistic rationale behind the
hygiene hypothesis has been challenged. Theories of an
imbalance between Th1/Th2 responses and reduced
immune suppression by regulatory T cells have been dis-
cussed as alternative explanations [3,4]. Widespread
attention has been given to the possible link between M.
tuberculosis infection and allergy, in which M. tuberculosis
infection has been suggested to promote a reduction in
allergic disorders. Previously, increased levels of total IgE
has been documented in TB patients compared to controls
[5-8], and a decline in total IgE after TB treatment has
been observed [5-7,9]. However, total IgE is a poor marker
for allergy because it can also increase after parasitic infec-
tion. Specific IgE to different allergens correlates well with
allergic disease. Despite the importance of specific IgE as
a marker for allergic disease, limited and conflicting
results have been reported on the association between
specific IgE and TB [9,10]. The present work is an exten-
sion of a previous study, which showed an increase in
allergic sensitisation among TB patients compared to
healthy controls [8]. The main goals of this paper were to
study whether the allergic sensitisation changed after TB
treatment, and to confirm the finding of higher levels of
allergic sensitisation in TB patients compared to more
optimally selected controls matched by gender, age, and
socio-economic status. Additionally, we wanted to com-
pare the expression of cytokines between the groups.
Finally, the association between allergic sensitisation and
Bacillus Calmette-Guérin (BCG) vaccination scar was
evaluated in healthy controls. To answer these questions,
specific IgE antibodies to a range of inhalant allergens
(Phadiatop), total IgE, and cytokine responses in the sera




The Bangladesh Rural Advancement Committee (BRAC)
organised the TB control programme in cooperation with
the National TB Programme (NTB) [11]. The present
study was a longitudinal study. Sera were collected from
108 TB patients at the time of diagnosis, prior to initiation
of treatment, and from 216 healthy controls living in the
Sunamganj district in Northern Bangladesh during 2004
and 2005. In addition, sera were collected from a sub-
group of 71 TB patients after completed treatment. The
Sunamganj district is an isolated rural area inhabited
mainly by farmers. Collection of the sera was organised by
a local consultant company, Destiny Associates, in coop-
eration with BRAC and the NTB. The patients were
recruited among sputum smear positive (SS+) patients liv-
ing in 4 upazillas (sub-districts) in Sunamganj (Chatak,
Derai, Duarabazar and Sunamganj Sadhar). The controls
were recruited by our field staff from the same villages as
the patients and had no history of previous TB. The con-
trols were recruited to match the TB patients on group
level by gender, age, and socio-economic status. Socio-
economic status was defined by landownership (land-
owner or landless), which type of housing (brick, tin-shed
or cathca (non-permanent)), education (illiterate, pri-
mary, or secondary school), and occupation (three catego-
ries: day labourer/disabled/unemployed, student/
housewife/worker (salary), and own-enterprise/farming
own land). The four different variables were given a score
and added for each participant; 0 was the lowest and 8 was
the highest socio-economic status. Informed consent was
obtained from the patients and healthy controls. Charac-
terisations of the participants of the different groups are
listed in Table 1. The controls and post-treatment patients
were paid Tk 600 (about US $9.00) for each blood sam-
ple. The following patients were excluded from the com-
parison of patients before and after treatment: patients
who did not want to give blood, patients who defaulted
(quit the treatment before it was completed) or failed
treatment (the treatment was not successful), or patients
who died.
The blood samples were centrifuged and frozen locally
before they were shipped on dry ice to Norway. The
patients were interviewed by the field staff using a ques-
tionnaire for information about allergy (yes/no), smok-
ing, socio-economic status, and BCG vaccination
(reported as visible BCG scar or not). The project was
approved by the regional Committee for Medical Research
Ethics in Western Norway and the Committee for Medical
Research Ethics of Bangladesh Medical Research Council
(BMRC).
Tuberculosis treatment regimen
The patients were treated according to the NTP standard
regimen for new SS+ patients; 2 months with isoniazide,
rifampicin, pyramizinamide, and ethambutol followed by
4 months of isoniazide and rifampicin.
Specific and total IgE
Specific and total IgE were analysed by ImmunoCAP 1000
r system in 2006 and 2007. This is an automated allergy-
testing system from Phadia AB (Uppsala, Sweden). The
Phadiatopr was used to analyse specific IgE to a combina-
tion of different inhalant allergens (cat, dog, horse, timo-
thy, birch, hazel, mugwort, wall pellitory, mold fungus
(cladosporium herbarium), and house dust mite (Dermat-BMC Infectious Diseases 2009, 9:100 http://www.biomedcentral.com/1471-2334/9/100
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ophagoides pteronyssinus, Der p1 and Der p2)). We chose to
use the European Phadiatop test on recommendation
from the producer as the most relevant broad spectre
allergy test containing several common allergens in Bang-
ladesh. The test was performed according to the manufac-
turer's instructions, and the Phadiatop results are
expressed in PAU/l (Phadia Arbitrary Units/l), while total
IgE results are expressed in kU/l.
Cytokines
Cytokines were analysed by multiplex bead immunoassay
(Luminex 100, Luminex Corporation, Austin, TX, USA)
according to the manufacturer's instructions and using
kits from Biosurce (Cat. No.; LHC 0001, LHC 0151, LHC
9121, LHC 0171, Invitrogen, Carlsbad, CA, USA). The
cytokines were quantified (pg/ml) by using standards sup-
plied with the kits. The detection limit of the different
cytokines were 3 pg/ml (IL-5, IL-6, IL-8), 5 pg/ml (IFNγ,
IL-4, IL-10), 6 pg/ml (IL-2), 10 pg/ml (IL-12p70, IL-15, IL-
17, tumour necrosis factor (TNF)α) and 15 pg/ml (Gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF),
IL-1β), as given by the manufacturer. More than 20% of
the test sera in one of the groups had to be above the
detection limit to be analysed in a statistical model.
Statistics
There is a strong correlation between Phadiatop quantifi-
cations and the sum of the individually measured specific
IgE antibodies to the allergens included in the Phadiatop
assay [12,13]. The rate of respiratory allergic disease has
been shown to increase linearly with the increase in spe-
cific IgE (Phadiatop) [13,14]. Consequently, we have ana-
lysed the results with a continuous scale instead of the
negative/positive cut-off value as suggested by the manu-
facturer. Non-parametric tests were used to analyse spe-
cific and total IgE due to skew distributions of the data.
The Mann-Whitney test for two independent groups was
applied to compare TB patients with healthy controls, and
differences between TB patients before and after treatment
were analysed by Wilcoxon signed-rank test for paired
data. The median with a 95% bootstrapped confidence
interval for specific and total IgE values were estimated
using the bootstrapped method [15] with 10,000 boot-
strap replications.
To adjust for possible confounders when comparing
healthy controls to TB patients, a multivariate logistic
regression model was used. We wanted to estimate the
association of TB and allergy using tuberculosis disease as
the dependent variable. The independent variables in the
multivariate logistic regression analyses were Phadiatop,
reported allergy, BCG status, and smoking. Phadiatop and
reported allergy were run separately with BCG status and
smoking to avoid colinearity [16]. The Phadiatop values
were stratified into class 0–2 (from 0 to 3.49 PAU/l) and
class 3–6 (3.50 to 100 PAU/l) before including them in
the logistic regression model. The study population was
matched on group level by gender, age, and socio-eco-
nomic status, and therefore not included in the analyses
as confounders. In addition, the controls were analysed
separately to look at the association between visible BCG
scar and Phadiatop result. The control group was divided
in two based on the Phadiatop values (class 0–2 and class
3–6) and used as the dependent variable in the logistic
regression model. Gender, age, and socio-economic sta-
tus, visible BCG scar and smoking were included in the
model as independent variables, since no matching was
performed at this level. The adjusted odds ratios (AOR)
with 95% confidence intervals and two-sided p-values
were given. These analyses were performed using the Sta-
tistical Package for Social Science (SPSS) for Windows,
version 14.0.
Table 1: Distribution and characterisation of the groups
Controls Tuberculosis patients
A: Before treatment B: Subgroup;
follow-up analyses
Number 216 108 71
Gender (%) (females, males) 33.5/66.5 33.3/66.7 27.8/72.2
Age, Mean ± SD 41.1 ± 15.5 40.1 ± 14.8 40.4 ± 15.0
Smoking, no/yes (%) 53.2/46.8 59.5/40.5 62.5/37.5
BCG scar, absent/present/unknown (%), 75.2/18.3/6.4 91/8.1/0.9 90.3/9.7/0
Reported allergy, n (%) 14 (6.4) 21 (18.9) 13 (18.1)
Weeks of TB symptoms
Mean ± SD
10.5 ± 5.7 10.4 ± 5.9
BCG = Bacillus Calmette-Gu, rin, A: These patients were included in the analyses between tuberculosis patients and healthy controls. B: The 
subgroup consisted of 71 patients which were followed-up after treatment. These patients were included in paired-analyses concerning before and 
after tuberculosis treatment.BMC Infectious Diseases 2009, 9:100 http://www.biomedcentral.com/1471-2334/9/100
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The cytokine data had a skewed distribution and there
were a high number of ties in the data. Therefore, we used
a permutation test to estimate p-values for comparison of
two independent groups to evaluate differences between
TB patients before and after treatment [16-18]. A Bonfer-
roni correction was used to correct for 9 multiple compar-
isons giving a statistical significance level of 0.05/9 =
0.0056. The statistical software R version 2.2.1 for win-
dows was used to perform the permutations [18].
Results
Comparison of allergy markers among TB patients before 
and after treatment
The levels of specific IgE (p = 0.0005) and total IgE (p =
0.0005) were significantly lower in TB patients after treat-
ment compared to those before treatment (Fig. 1a and
1b). Analysis by gender revealed similar differences (Table
2). There was no significant difference between genders
within each group.
Comparison of allergy markers among TB patients and 
controls
TB patients had significantly higher levels of both specific
IgE (p = 0.001) and total IgE (p = 0.016) (Fig. 1c and 1d)
compared to healthy controls. Separation of the groups by
gender revealed similar differences for specific IgE, while
the total IgE levels were not significantly different (Table
3). There were no gender differences within each group
(data not shown). Allergy reported in the questionnaire
was indicated by 18.9% of the TB patients and by 6.0% in
the control group. To adjust for possible confounders, a
multivariate logistic regression model was used to study
the association between TB disease at diagnosis and
allergy (Table 4). To increase the probability of clinical
symptoms, we used a higher cut-off value than the cut-off
value suggested by the manufacturer; negative (class 0)/
positive (class 1 to 6). Phadiatop values were therefore
stratified into class 0–2 (from 0 to 3.49 PAU/l) and class
3–6 (3.50 to100 PAU/l). However, we also found a signif-
icant difference using the cut-off value recommended by
the manufacturer (< 0.35 = negative, > 0.35 = positive)
(AOR = 1.96, CI 1.01 – 3.78, p = 0.046). In total, 60.2%
of the TB group, and 76.8% of the control group were dis-
tributed to class 0–2, while 39.8% and 23.6%, respec-
tively, were distributed to class 3–6. The adjusted logistic
regression analyses revealed that allergy was positively
associated with TB disease. Smoking had no effect on the
prediction for TB. However, the presence of BCG scar was
associated with reduced TB disease (Table 4).
Cytokines
In general, the concentrations were low for most of the
cytokines, except for IL-6 and IL-8. Significantly higher
levels of IL-6 were found in TB patients at the time of diag-
nosis compared to controls (p < 0.0001) (Fig. 2a). A clear
reduction was observed in IL-6 levels after TB treatment (p
< 0.0001) (Fig. 2b). On the other hand, there was no sig-
nificant difference in IL-8 concentrations in TB patients
before treatment as compared with controls (p = 0.17) or
in TB patients before and after TB treatment (p = 0.40).
The levels of IFNγ were significantly higher in TB patients
before treatment (mean ± SD: 9.1 pg/ml ± 10.8) com-
pared with controls (mean ± SD: 6.7 pg/ml ± 17.9) (p <
0.0001). However, no significant difference was found in
IFNγ concentration between TB patients before and after
treatment (p = 0.10). There was no significant difference
in the concentrations of GM-CSF, IL-1β, IL-2, TNFα, IL-
12p70, and IL-15 between TB patients before treatment
and controls, or between TB patients before and after
treatment. The serum levels of IL-4, IL-5, IL-10 and IL-17
were below the detection limit of this system.
Association between BCG and allergy markers in the 
control group
To investigate the effect of visible BCG scar alone, we also
analysed the control group separately by categorizing the
Table 2: Comparison of tuberculosis patients before (TBbefore) and after (TBafter) treatment (subgroup, n = 71).
Marker Group Median 95% bootstrapped CI Significance p
Total IgE TBbefore 2636 2078 – 3954 0.0005 *
(kU/l) TBafter 1781 1224 – 2525
TBbefore male 2587 1972 – 4058
TBafter male 1730 1154 – 2651 0.0005 *
TBbefore female 2697 1559 – 5000
TBafter female 2285 925 – 3017 0.015 *
Phadiatop TBbefore 1.89 1.10 – 2.79
(PAU/l) TBafter 1.44 0.86 – 1.99 0.0005 *
TBbefore male 1.89 1.03 – 2.94
TBafter male 1.44 0.85 – 2.61 0.0005 *
TBbefore female 1.97 0.70 – 3.98
TBafter female 1.34 0.36 – 2.22 0.004 *
Wilcoxon Signed-rank TestBMC Infectious Diseases 2009, 9:100 http://www.biomedcentral.com/1471-2334/9/100
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controls into two groups depending on the Phadiatop val-
ues (class 0–2 and class 3–6). In a logistic regression
model, the presence of a BCG scar was associated with a
reduced risk for developing allergic sensitisation (AOR =
0.32, CI 0.11 – 0.93, p = 0.037). Neither age, socio-eco-
nomic status, gender, nor smoking had a statistically sig-
nificant effect on the association between TB and BCG
scar. No significant difference was observed using the cut-
off value as suggested by the manufacture (< 0.35 = nega-
tive, > 0.35 = positive).
Discussion
We observed reduced levels of IL-6, specific and total IgE
after successful TB treatment. The levels of IFNγ, IL-6, spe-
cific and total IgE were higher in TB patients compared to
healthy controls. Furthermore, an inverse association was
Both specific (a) and total (b) IgE were reduced after successful treatment of TB patients Figure 1
Both specific (a) and total (b) IgE were reduced after successful treatment of TB patients. Total (c) and specific 
(d) IgE were higher in TB patients compared with healthy controls. The box plot indicates the 25 percentile, the median and 
the 75 percentile. Error bars above and below the box illustrate the maximum and minimum values.BMC Infectious Diseases 2009, 9:100 http://www.biomedcentral.com/1471-2334/9/100
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found between the presence of a BCG scar and specific
IgE.
The key finding of reduced levels of specific and total IgE
after successful treatment, indicates a reduction in allergic
sensitisation in TB patients after treatment for TB. To our
knowledge no longitudinal studies analysing TB patients
before and after treatment have been published previ-
ously on specific IgE using the Phadiatop test. There is a
positive correlation between Phadiatop levels and allergy
symptoms [13], and therefore it is possible that the
observed difference is clinically relevant. In contrast to our
study, Mungan et al. observed a lower percentage of posi-
tive Phadiatop test and skin prick test in TB patients with
active disease compared to patients with a past history of
TB [10]. However, the authors did not follow the same
patients before and after treatment, and only 31 patients
with a history of TB were analysed. Adams et al. [9] found
no difference in specific IgE towards house dust mite,
cockroach or Bermuda grass before and after TB treat-
ment. The Phadiatop test includes a broader selection of
allergens, and we have also included significantly more
patients, which might explain the conflicting results. The
finding of reduced level of total IgE after successful TB
treatment is supported by several other studies [5-7,10].
Both specific and total IgE levels were higher in TB
patients as compared to controls, confirming the findings
of our previous study [8]. In contrast to our study, Adams
et al. [9] found no difference in specific IgE among 23 TB
patients and 33 healthy controls. The controls were highly
improved in the present study by matching gender, age,
and socio-economic status. After adjusting for smoking
and the presence of BCG scar, the multivariate logistic
regression model used showed a positive association
between TB and the markers for allergy (specific IgE or
reported allergy in the questionnaire). Whether individu-
als with allergy have an increased risk for developing TB,
or TB patients have an increased risk for developing
allergy is a difficult question. However, patients with
active TB have distinct immunological features that are
different from individuals with latent TB. For example,
healthy individuals with latent TB have increased IL-4δ2
mRNA levels (an antagonist of IL-4) rather than increased
IL-4 mRNA levels, as observed in progressive TB [19]. To
our knowledge, the only prospective study performed on
this issue followed 10 M. tuberculosis infected health-care
workers for 5 years, out of which 6 developed TB. [20].
Prior to disease development, they had increased intracel-
lular IL-4 and reduced IFNγ levels in their CD8+ and γδ+ T
cell subsets in response to M. tuberculosis antigen stimula-
tion. Although small, this study indicates a predisposition
for a Th2 response. Only 5–10% of infected individuals
develop TB disease, and therefore it is conceivable that
those particular individuals might be genetically predis-
posed for a Th2 response.
There are some limitations to this study. We were not able
to adjust for helminthic infection and HIV in our study,
Table 3: Comparison of TB patients before treatment (n = 108) and healthy control (n = 216).
Marker Group Median 95% bootstrapped CI Significance
p-value
Total IgE (kU/l) Control 2160 1799 – 2835 0.016 *
TB 2868 2514 – 4060
Control male 2710 1800 – 3422 0.121
TB male 3050 2269 – 4098
Control female 1928 1427 – 2409 0.052
TB female 2697 2150 – 5000
Phadiatop Control 1,21 0.92 – 1.51 0.001 *
(PAU/l) TB 2,24 1.53 – 2.78
Control male 1.31 0.92 – 1.87 0.008 *
TB male 1.98 1.18 – 3.30
Control female 1.02 0.65 – 1.37 0.044 *
TB female 2.40 1.00 – 3.55
MannWhitney
Table 4: The association of TB and allergy markers in TB 
patients before treatment (n = 108) as compared with healthy 
controls (n = 216).
AOR (95%CI) P-value
Phadiatop (Class 0–2/class 3–6) 2.19 (1.30 – 3.68) 0.003
BCG scar (not visible/visible) 0.45 (0.21 – 0.99) 0.046
Smoking (no/yes) 0.72 (0.43 – 1.18) 0.186
Reported allergy (no/yes) 3.27 (1.57 – 6.83) 0.002
BCG scar (not visible/visible) 0.38 (0.18 – 0.84) 0.017
Smoking (no/yes) 0.30 (0.47 – 1.26) 0.297
Multivariate logistic regression models were used to estimate 
adjusted odds ratio (AOR) for TB as the dependent variable. Either 
Phadiatop (ImmunoCAP class 0–2 and class 3–6) or reported allergies 
were included in the analyses as independent variables together with 
visible BCG scar and smoking.BMC Infectious Diseases 2009, 9:100 http://www.biomedcentral.com/1471-2334/9/100
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which both represent confounders. Specific IgE towards
helminths and M. tuberculosis [21] itself could also partly
explain the increased level of total IgE and the specificity
of the total IgE. There could be a general polyclonal stim-
ulation, which could explain the increased levels of IgE. A
reduction of IgE and IL-6 after TB treatment might also be
explained by a reduction of a polyclonal stimulation or
the use of anti-tuberculosis drugs, but to our knowledge a
beneficial effect by anti-tuberculosis drugs on IgE levels
has not been reported. Another limitation to the study is
the questionnaire-based diagnosis of allergic disorder.
People in developing countries like Bangladesh may not
be familiar with the term allergy, and it is possible that
sick TB patients might report more symptoms than
healthy individuals. Therefore, the results regarding the
questionnaire should be read with caution. We tried to
compensate for some of this limitation by having ques-
tionnaires filled in by the field staff.
Additionally, we examined the difference in the cytokine
profile (Th1-, proinflammatory-, Th2-, and Treg
cytokines) in TB patients and controls, and between TB
patients before and after treatment. Significantly higher
levels of the proinflammatory cytokine IL-6 and the Th1
cytokine IFNγ were observed in TB patients compared to
controls. The levels of IL-6 were reduced upon successful
TB treatment. Previous studies have also shown a higher
level of IL-6 in serum from TB patients compared to con-
trols [21,22], as well as a decrease after TB treatment [21].
Since IL-6 has been associated with protection against M.
tuberculosis, it seems reasonable that IL-6 is elevated in
patients with TB disease. However, the reduced levels of
IL-6 after TB treatment might also be due to reduced aller-
gic sensitisation. Previously, IFNγ has been found to be
increased in serum from TB patients relative to controls,
confirming our results [21-25]. In contrast to our observa-
tion, a decrease in IFNγ concentration during treatment
has previously been found [22,26]. There are some limita-
tions to the cytokine data, and thus a more complete
cytokine profile with respect to Th1, Th2 and Treg
cytokines could not be established. For some of the
cytokines there were only some individuals with detecta-
ble levels and hence, comparison of the groups with
respect to IL-4, IL-5, IL-10 and IL-17 could not be per-
formed. Therefore, it is uncertain whether these cytokines
were absent from the serum or too low for detection by
the Luminex system. Some cytokines are sensitive to stor-
age [27]. Variable clotting time, freeze-thaw cycles, and
processing of the samples can also influence the degrada-
tion. These factors prohibited exact quantification of
cytokines in the serum, but caution was taken to handle
the samples equally, allowing us to compare the data from
the different groups.
To investigate the effect of BCG scar alone (without TB
disease), we also analysed the control group separately by
categorising the controls into two groups depending on
the Phadiatop values (class 0–2 and class 3–6). The pres-
ence of BCG scar was associated with a reduced risk of
developing allergic sensitisation. This finding agrees with
the idea above, and points to a similar anti-allergic effect
of live M. bovis, BCG. If BCG vaccination protects against
The levels of proinflammatory cytokine IL-6 were (a), significantly higher in TB patients compared with healthy controls (*p <  0.0001), and (b) significantly reduced in TB patients after treatment (TBafter) compared with before started treatment (TBafter) Figure 2
The levels of proinflammatory cytokine IL-6 were (a), significantly higher in TB patients compared with 
healthy controls (*p < 0.0001), and (b) significantly reduced in TB patients after treatment (TBafter) compared 
with before started treatment (TBafter). The IL-6 levels are given as means ± standard deviation (SD).BMC Infectious Diseases 2009, 9:100 http://www.biomedcentral.com/1471-2334/9/100
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development of allergy, and there are more people in the
TB group who are not BCG vaccinated, then this could
partly explain the higher percentage of allergic sensitisa-
tion among TB patients. Previous studies that have inves-
tigated the effect of BCG vaccination on allergy, have been
diverging, maybe due to reasons described elsewhere [19].
It is difficult to investigate the effect of BCG alone because
the healthy controls have probably been exposed to
mycobacteria, either M. tuberculosis or other environmen-
tal mycobacteria. Additionally, the participants in the
study might have been vaccinated even though one could
not observe a BCG scar. Therefore, the result regarding the
protective effect of BCG scar should be read with caution.
To summarise, we observed a reduced level of allergic sen-
sitisation after successful TB treatment, which may be due
to down-regulation by dead or dying M. tuberculosis
bacilli, a direct effect of anti-tuberculosis drugs, or elimi-
nation of a general stimulation by M. tuberculosis. TB
patients seem to be more allergic sensitised than healthy
controls confirming our previous finding of enhanced
allergic sensitisation in TB patients. This may indicate that
TB patients are more susceptible to develop allergy or that
allergy patients are more disposed to develop tuberculosis
upon infection with M. tuberculosis. The inverse associa-
tion of allergic sensitisation and visible BCG scar adds
additional support to the hygiene hypothesis, and might
have implications for prevention of allergic diseases in the
future.
Conclusion
In the present study we observed a reduction of allergic
sensitisation in TB patients after successful treatment.
Additionally, a higher degree of allergic sensitisation in TB
patients compared to healthy controls was found. Further-
more, we observed a negative association between allergy
development and visible BCG scar.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
LKE participated in the designing of the study, collection
of the sera, performing of the analyses, and interpretation
of the data, and she drafted the manuscript. DGS partici-
pated in the collection of the sera, LMD advised and per-
formed some of the most complicated statistical analyses,
KAB performed the Luminex analyses, and GH and HGW
participated in the design of the study, collection of the
sera and revision of the manuscript. All co-authors have
read and approved the manuscript.
Acknowledgements
We thank Mohammed Akramul Islam (Bangladesh Rural Advancement 
Committee (BRAC), Mohakali, Bangladesh) and Vikarunessa Begum 
(National Tuberculosis Control Programme, Directorate General of 
Health Services, Bangladesh) for making this study possible in Bangladesh. 
Furthermore, we thank Dr. Steve Plettner (Destiny Associates, Sylhet, 
Bangladesh) for organising the collection of the sera in Bangladesh, and Dr. 
Per Ivar Gaarder (Ullevål University Hospital, Oslo) for helping with the IgE 
analyses. This paper was supported by the Norwegian Foundation for 
Health and Rehabilitation through the Norwegian Association for Asthma 
and Allergy, and the Norwegian Institute of Public Health.
References
1. Raviglione MC: The TB epidemic from 1992 to 2002.  Tuberculo-
sis 2003, 83:4-14.
2. Strachan DP: Hay fever, hygiene, and household size.  BMJ 1989,
299:1259-1260.
3. Wills-Karp M, Santeliz J, Karp CL: The germless theory of allergic
disease: revisiting the hygiene hypothesis.  Nature Reviews
Immunology 2001, 1:69-75.
4. Romagnani S: Coming back to a missing immune deviation as
the main explanatory mechanism for the hygiene hypothe-
sis.  J Allergy Clin Immunol 2007, 119:1511-1513.
5. Ohrui T, Zayasu K, Sato E, Matsui T, Sekizawa K, Sasaki H: Pulmo-
nary tuberculosis and serum IgE.  Clin Exp Immunol 2000,
122:13-15.
6. Suzuki N, Kudo K, Sano Y, Ito K: Can Mycobacterium tuberculo-
sis infection prevent asthma and other allergic disorders?  Int
Arch Allergy Immunol 2001, 124:113-116.
7. Lienhardt C, Azzurri A, Amedei A, Fielding K, Sillah J, Sow OY, Bah B,
Benagiano M, Diallo A, Manetti R, et al.: Active tuberculosis in
Africa is associated with reduced Th1 and increased Th2
activity in vivo.  Eur J Immunol 2002, 32:1605-1613.
8. Ellertsen LK, Wiker HG, Egeberg NT, Hetland G: Allergic sensiti-
sation in tuberculosis and leprosy patients.  Int Arch Allergy
Immunol 2005, 138:217-224.
9. Adams JF, Scholvinck EH, Gie RP, Potter PC, Beyers N, Beyers AD:
Decline in total serum IgE after treatment for tuberculosis.
Lancet 1999, 353:2030-2033.
10. Mungan D, Sin BA, Celik G, Gurkan OU, Acican T, Misirligil Z:
Atopic status of an adult population with active and inactive
tuberculosis.  Allergy Asthma Proc 2001, 22:87-91.
11. Islam MA: Cost-effectiveness of community health workers in
tuberculosis control in Bangladesh.  Bulletin of the World Health
Organisation 2002, 80:445-450.
12. Williams PB, Siegel C, Portnoy J: Efficacy of a single diagnostic
test for sensitization to common inhalant allergens.  Ann
Allergy Asthma Immunol 2001, 86:196-202.
13. Matricardi PM, Nisini R, Biselli R, D'Amelio R: Evaluation of the
overall degree of sensitization to airborne allergens by a sin-
gle serologic test: implications for epidemiologic studies of
allergy.  J Allergy Clin Immunol 1994, 93:68-79.
14. Simpson A, Soderstrom L, Ahistedt S, Murray CS, Woodcock A, Cus-
tovic A: IgE antibody quantification and the probability of
wheeze in preschool children.  Journal of Allergy and Clinical Immu-
nology 2005, 116:744-749.
15. Efron B, Tibshirani RJ: An introduction to the Bootstrap.  USA;
Chapman & Hall/CRC; 1993:436. 
16. Kirkwood BR, Sterne JAC: Essential Medical Statistics.  Oxford;
Blackwell Science; 2003:502. 
17. Lehmann EL, D'Abrera HJM: Nonparametrics: Statistical Meth-
ods Based on Ranks.  Germany; Springer Science+Business Media;
2006:480. 
18. Statistical software R, version 2.2.1 for Windows.  R Founda-
tion for Statistical Computing, Vienna, Austria; 2006. 
19. Rook GA, Hamelmann E, Rosa BL: Mycobacteria and allergies.
Immunobiology 2007, 212:461-473.
20. Ordway DJ, Costa L, Martins M, Silveira H, Amaral L, Arroz MJ, Ven-
tura FA, Dockrell HM: Increased Interleukin-4 production by
CD8 and gammadelta T cells in health-care workers is asso-
ciated with the subsequent development of active tuberculo-
sis.  J Infect Dis 2004, 190:756-766.
21. Verbon A, Juffermans N, Van Deventer SJ, Speelman P, Van Deute-
kom H, Van Der PT: Serum concentrations of cytokines in
patients with active tuberculosis (TB) and after treatment.
Clin Exp Immunol 1999, 115:110-113.
22. Rey AD, Mahuad CV, Bozza VV, Bogue C, Farroni MA, Bay ML, Bot-
tasso OA, Besedovsky HO: Endocrine and cytokine responses inPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2009, 9:100 http://www.biomedcentral.com/1471-2334/9/100
Page 9 of 9
(page number not for citation purposes)
humans with pulmonary tuberculosis.  Brain Behav Immun 2007,
21:171-179.
23. Shigehara K, Shijubo N, Ohmichi M, Yamada G, Takahashi R, Oka-
mura H, Kurimoto M, Hiraga Y, Tatsuno T, Abe S, et al.: Increased
levels of interleukin-18 in patients with pulmonary sarcoido-
sis.  Am J Respir Crit Care Med 2000, 162:1979-1982.
24. Morosini M, Meloni F, Marone BA, Paschetto E, Uccelli M, Pozzi E,
Fietta A: The assessment of IFN-gamma and its regulatory
cytokines in the plasma and bronchoalveolar lavage fluid of
patients with active pulmonary tuberculosis.  Int J Tuberc Lung
Dis 2003, 7:994-1000.
25. Deveci F, Akbulut HH, Turgut T, Muz MH: Changes in serum
cytokine levels in active tuberculosis with treatment.  Media-
tors Inflamm 2005, 2005:256-262.
26. Berktas M, Guducuoglu H, Bozkurt H, Onbasi KT, Kurtoglu MG,
Andic S: Change in serum concentrations of interleukin-2 and
interferon-gamma during treatment of tuberculosis.  J Int Med
Res 2004, 32:324-330.
27. Kenis G, Teunissen C, De Jongh R, Bosmans E, Steinbusch H, Maes M:
Stability of interleukin 6, soluble interleukin 6 receptor,
interleukin 10 and CC16 in human serum.  Cytokine 2002,
19:228-235.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/9/100/pre
pub